Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Assembly Biosciences Inc ASMB

Healthcare Biotechnology
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle... see more

Recent & Breaking News (NDAQ:ASMB)

SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Ventrus Biosciences, Inc. and Certain Officers -- VTUS

Globe Newswire May 21, 2013

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To Contact The Firm

PR Newswire May 18, 2013

Ventrus Biosciences, Inc. Sued by Investor

PR Newswire May 17, 2013

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventrus Biosciences, Inc. - VTUS

PR Newswire May 15, 2013

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $300,000 From Investment in Ventrus Biosciences, Inc. to Contact Brower Piven Before the July 8, 2013 Lead Plaintiff Deadline -- VTUS

Globe Newswire May 13, 2013

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Ventrus Biosciences, Inc. of Class Action Lawsuit and the Deadline of July 8, 2013 to Seek a Lead Plaintiff Position -- VTUS

Globe Newswire May 13, 2013

Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Ventrus Bioscences, Inc. (NASDAQ: VTUS)

Marketwired May 12, 2013

Bronstein, Gewirtz & Grossman, LLC Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.

PR Newswire May 10, 2013

Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.

PR Newswire May 10, 2013

VENTRUS BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ventrus Biosciences, Inc. - VTUS

Marketwired May 9, 2013

Scott+Scott, Attorneys at Law, LLP Files Securities Class Action Lawsuit Against Ventrus Biosciences, Inc. -- VTUS

Globe Newswire May 9, 2013

Zeldes & Haeggquist, LLP Announces Investigation of Ventrus Biosciences, Inc.

Business Wire April 8, 2013

Holzer Holzer & Fistel, LLC Announces Investigation into Ventrus Biosciences, Inc.

Business Wire February 12, 2013

Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference

Troy Schwensen February 11, 2013

Ventrus Biosciences Announces Full Exercise of Overallotment Option by Underwriters

Troy Schwensen February 7, 2013

Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues

Marketwired January 31, 2013

Ventrus Biosciences Announces $20 Million Financing

Troy Schwensen January 30, 2013

Free Research Reports on KLIC, OXF, SWIR and VTUS Issued by the Bedford Report

Marketwired January 30, 2013

Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock

Troy Schwensen January 29, 2013

Perfect Trade Setups, How to Play SGYP, CLSP, VTUS and PGNX

Marketwired January 3, 2013